Latest News
Alderley Park, 22 November 2022 – Blueberry Therapeutics are pleased to announce that their novel cream formulation for the treatment of atopic dermatitis (BB1511) has been nominated for clinical development.
This nomination decision w...
Infex Therapeutics, a leading anti-infectives specialist, is pleased to announce the first subjects have been dosed in Phase I study in healthy volunteers evaluating the Company's lead drug candidate RESP-X, a new anti-virulence therapy to treat P...
Manchester, UK. Biorelate Limited (“Biorelate”) and CCC (Copyright Clearance Center), today announced a strategic integration. Biorelate’s customers will immediately have the option to access subscription-only scholarly art...
November 7, 2022 – First Choice Neurology (FCN), the largest neurology group in the U.S. with more than 41 facilities in six Florida counties and services at 35 major hospitals, has partnered with U.K-based Cytox to become the first pra...
• OBT licenses to Genmab the rights to a novel, pre-clinical first-in-class immuno-oncology (IO) antibody.
• Under its Commercial License Agreement with OBT, Genmab will obtain the exclusive right to develop and commercialize novel anti...